Body mass index and quality of life in people living with HIV

References

• Achhra, A., Mocroft, A., Reiss, P., Sabin, C., Ryom, L., de Wit, S., Smith, C. J., d’Arminio Monforte, A., Phillips, A., Weber, R., Lundgren, J., & Law, M. G. (2016). Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D:A:D study. HIV Medicine, 17(4), 255–268. https://doi.org/10.1111/hiv.12294
   PubMed Web of Science ®Google Scholar
• Achhra, A., Sabin, C., Ryom, L., Monforte, A. d., Wit, S. d., Phillips, A., Pradier, C., Lundgren, J. D., & Law, M. (2017). Body mass index and the risk of serious non-AIDS events: The D:A:D study. CROI, 693.
   Google Scholar
• Andersen, R., Bozzette, S. A., Shapiro, M. F., Stclair, P. A., Morton, S. C., Crystal, S., Goldman, D. P., Wenger, N. S., Gifford, A., Leibowitz, A., Asch, S. M., Berry, S. H., Nakazono, T. T., Heslin, K. C., Cunningham, W., Anderson, R., Katz, M., Stein, M., Hays, R. D., … Athey, L. A. (2006). Disparities in care for HIV patients: Results of the HCSUS study. RAND Corporation. https://doi.org/10.7249/RB9171
   Google Scholar
• Arenas-Pinto, A., Copas, A., Weller, I., Grant, A., Dunn, D., Bhaskaran, K., Carr, A., Reiss, P., Edwards, S., Worm, S. W., Overton, T., Martinez, E., Hoy, J., Cahn, P., & Weber, R. (2007). Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS (London, England), 21(18), 2455–2464. https://doi.org/10.1097/QAD.0B013E3282F08CDC
   PubMed Web of Science ®Google Scholar
• Ballantyne, G. H. (2003). Measuring outcomes following bariatric surgery: Weight loss parameters, improvement in co-morbid conditions, change in quality of life and patient satisfaction. Obesity Surgery, 13(6), 954–964. https://doi.org/10.1381/096089203322618867
   PubMed Web of Science ®Google Scholar
• Bangert, E., Wakani, L., Merchant, M., Strand, V., & Touma, Z. (2019). Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: Review of clinical studies. Patient Related Outcome Measures, 10, 1. https://doi.org/10.2147/PROM.S134326
   PubMed Web of Science ®Google Scholar
• Becofsky, K. M., Wing, E. J., Wing, R. R., Richards, K. E., & Gillani, F. S. (2016). Obesity prevalence and related risk of comorbidities among HIV+ patients attending a New England ambulatory centre. Obesity Science & Practice, 2(2), 123. https://doi.org/10.1002/osp4.38
   PubMedGoogle Scholar
• Bourgi, K., Jenkins, C. A., Rebeiro, P. F., Palella, F., Moore, R. D., Altoff, K. N., Gill, J., Rabkin, C. S., Gange, S. J., Horberg, M. A., Margolick, J., Li, J., Wong, C., Willig, A., Lima, V. D., Crane, H., Thorne, J., Silverberg, M., Kirk, G., … Koethe, J. R. (2020). Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. Journal of the International AIDS Society, 23(4), 1–8. https://doi.org/10.1002/jia2.25484
   Web of Science ®Google Scholar
• CDC. (2021). HIV basics: Basic statistics. https://www.cdc.gov/hiv/basics/statistics.html
   Google Scholar
• CDC. (2022). HIV and men. https://www.cdc.gov/hiv/group/gender/men/index.html
   Google Scholar
• Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40(5), 373–383. https://doi.org/10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Cohen, M. H., French, A. L., Benning, L., Kovacs, A., Anastos, K., Young, M., Minkoff, H., & Hessol, N. A. (2002). Causes of death among women with human immunodeficiency virus infection in the Era of combination antiretroviral therapy. The American Journal of Medicine, 113(2), 91. https://doi.org/10.1016/S0002-9343(02)01169-5
   PubMed Web of Science ®Google Scholar
• Corica, F., Corsonello, A., Apolone, G., Lucchetti, M., Melchionda, N., & Marchesini, G. (2006). Construct validity of the Short Form-36 Health Survey and its relationship with BMI in obese outpatients. Obesity (Silver Spring, MD), 14(8), 1429–1437. https://doi.org/10.1038/oby.2006.162
   PubMed Web of Science ®Google Scholar
• Corless, I. B., Nicholas, P. K., McGibbon, C. A., & Wilson, C. (2004). Weight change, body image, and quality of life in HIV disease: A pilot study. Applied Nursing Research, 17(4), 292–296. https://doi.org/10.1016/S0897-1897(04)00076-X
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone, N., Tejidor, R., Medina, S., Barahona, I., & Ganesan, A. (2008). Obesity among patients with HIV: The latest epidemic. AIDS Patient Care and STDs, 22(12), 925. https://doi.org/10.1089/apc.2008.0082
   PubMed Web of Science ®Google Scholar
• DiBonaventura, M. d., Gupta, S., Cho, M., & Mrus, J. (2012). The association of HIV/AIDS treatment side effects with health status, work productivity, and resource use. AIDS Care, 24(6), 744–755. https://doi.org/10.1080/09540121.2011.630363
   PubMed Web of Science ®Google Scholar
• Eckard, A. R., & McComsey, G. A. (2020). Weight gain and integrase inhibitors. Current Opinion in Infectious Diseases, 33(1), 10–19. https://doi.org/10.1097/QCO.0000000000000616
   PubMed Web of Science ®Google Scholar
• Emamikia, S., Oon, S., Gomez, A., Lindblom, J., Borg, A., Enman, Y., Morand, E., Grannas, D., Vollenhoven, R. F. v., Nikpour, M., & Parodis, I. (2022). Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford, England), 61(12), 4752. https://doi.org/10.1093/rheumatology/keac185
   PubMed Web of Science ®Google Scholar
• Frank, A. P., De Souza Santos, R., Palmer, B. F., & Clegg, D. J. (2019). Determinants of body fat distribution in humans may provide insight about obesity-related health risks. Journal of Lipid Research, 60(10), 1710. https://doi.org/10.1194/jlr.R086975
   PubMed Web of Science ®Google Scholar
• Gakhar, H., Kamali, A., & M, H. (2013). Health-related quality of life assessment after antiretroviral therapy: A review of the literature. Drugs, 73(7), 651–672. https://doi.org/10.1007/s40265-013-0040-4
   PubMed Web of Science ®Google Scholar
• Gallant, J., Hsue, P. Y., Shreay, S., & Meyer, N. (2017). Comorbidities among US patients with prevalent HIV infection – A trend analysis. The Journal of Infectious Diseases, 216(12), 1525–1533. https://doi.org/10.1093/infdis/jix518
   PubMed Web of Science ®Google Scholar
• George, S., Bergin, C., Clarke, S., Courtney, G., & Codd, M. B. (2016). Health-related quality of life and associated factors in people with HIV: An Irish cohort study. Health and Quality of Life Outcomes, 14(1), 1–12. https://doi.org/10.1186/s12955-016-0517-4
   PubMedGoogle Scholar
• Gomez, M., Seybold, U., Roider, J., Härter, G., & Bogner, J. R. (2019). A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017. Infection, 47(1), 95–102. https://doi.org/10.1007/s15010-018-1227-0
   PubMed Web of Science ®Google Scholar
• Guadamuz, T. E., Lim, S. H., Marshal, M. P., Friedman, M. S., Stall, R. D., & Silvestre, A. J. (2012). Sexual, behavioral, and quality of life characteristics of healthy weight, overweight, and obese gay and bisexual men: Findings from a prospective cohort study. Archives of Sexual Behavior, 41(2), 385–389. https://doi.org/10.1007/s10508-011-9859-5
   PubMed Web of Science ®Google Scholar
• Herdman, M., Gudex, C., Lloyd, A., Janssen, M. F., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736. https://doi.org/10.1007/s11136-011-9903-x
   PubMed Web of Science ®Google Scholar
• Herrin, M., Tate, J. P., Akgün, K. M., Butt, A. A., Crothers, K., Freiberg, M. S., Gibert, C. L., Leaf, D. A., Rimland, D., Rodriguez-Barradas, M. C., Ruser, C. B., Herold, K. C., & Justice, A. C. (2016). Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 73(2), 228–236. https://doi.org/10.1097/QAI.0000000000001071
   PubMed Web of Science ®Google Scholar
• Hogg, R. S. (2018). Understanding the HIV care continuum. The Lancet HIV, 5(6), e269–e270. https://doi.org/10.1016/S2352-3018(18)30102-4
   PubMed Web of Science ®Google Scholar
• Hörchner, R., Tuinebreijer, W., & Kelder, H. (2001). Quality-of-life assessment of morbidly obese patients who have undergone a Lap-Band® operation: 2-year follow-up study: Is the MOS SF-36 a useful instrument to measure quality of life in morbidly obese patients? Obesity Surgery, 11(2), 212–218. https://doi.org/10.1381/096089201321577901
   PubMed Web of Science ®Google Scholar
• Jones, C. Y., Hogan, J. W., Snyder, B., Klein, R. S., Rompalo, A., Schuman, P., & Carpenter, C. C. (2003). Overweight and human immunodeficiency virus (HIV) progression in women: Associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort. Clinical Infectious Diseases, 37(SUPPL. 2), S69–S80. https://doi.org/10.1086/375889.
   PubMed Web of Science ®Google Scholar
• Koethe, J. R., Lagathu, C., Lake, J. E., Domingo, P., Calmy, A., Falutz, J., Brown, T. T., & Capeau, J. (2020). HIV and antiretroviral therapy-related fat alterations. Nature Reviews Disease Primers, 6(1), 48. https://doi.org/10.1038/s41572-020-0181-1.
   PubMed Web of Science ®Google Scholar
• Kolakowska, A., Maresca, A. F., Collins, I. J., & Cailhol, J. (2019). Update on adverse effects of HIV integrase inhibitors. Current Treatment Options in Infectious Diseases, 11(4), 372–387. https://doi.org/10.1007/s40506-019-00203-7
   PubMedGoogle Scholar
• Kumar, S., & Samaras, K. (2018). The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Frontiers in Endocrinology, 9(November), 1–14. https://doi.org/10.3389/fendo.2018.00705
   PubMedGoogle Scholar
• Levitt, N. S., Peer, N., Steyn, K., Lombard, C., Maartens, G., Lambert, E. V., & Dave, J. A. (2016). Increased risk of dysglycaemia in South Africans with HIV; especially those on protease inhibitors. Diabetes Research and Clinical Practice, 119, 41–47. https://doi.org/10.1016/j.diabres.2016.03.012
   PubMed Web of Science ®Google Scholar
• Lewden, C., Salmon, D., Morlat, P., Bévilacqua, S., Jougla, E., Bonnet, F., Héripret, L., Costagliola, D., May, T., & Chêne, G. (2005). Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: Emerging role of hepatitis and cancers, persistent role of AIDS. International Journal of Epidemiology, 34(1), 121–130. https://doi.org/10.1093/ije/dyh307
   PubMed Web of Science ®Google Scholar
• Lifson, A. R., Grandits, G., Gardner, E. M., Wolff, M., Pulik, P., Williams, I., Burman, W. J., & International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group (2015). Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment trial. HIV Medicine, 16(0 1), 88–96. https://doi.org/10.1111/hiv.12237.
   PubMedGoogle Scholar
• Magoni, M., Scarcella, C., Vassallo, F., Lonati, F., Carosi, G., Castelnuovo, F., Quiros-Roldan, E., Albini, L., Gennaro, N., Bishai, D., Tramarin, A., & Torti, C. (2011). The evolving burden of HIV infection compared with other chronic diseases in northern Italy. HIV Medicine, 12(3), 129–137. https://doi.org/10.1111/j.1468-1293.2010.00861.x
   PubMed Web of Science ®Google Scholar
• Mallon, P. W. G., Brunet, L., Hsu, R. K., Fusco, J. S., Mounzer, K. C., Prajapati, G., Beyer, A. P., Wohlfeiler, M. B., & Fusco, G. P. (2021). Weight gain before and after switch from TDF to TAF in a U.S. cohort study. Journal of the International AIDS Society, 24(4), e25702. https://doi.org/10.1002/JIA2.25702.
   PubMed Web of Science ®Google Scholar
• McMahon, C. N., Petoumenos, K., Hesse, K., Carr, A., Cooper, D. A., & Samaras, K. (2018). Eleven-year incident glucose disorders in treated HIV-infection. The St Vincent’s HIV and Diabetes Study. Short. Aids (London, England), 32(4), https://doi.org/10.1097/QAD.0000000000001709
   Google Scholar
• Miners, A., Phillips, A., Kreif, N., Rodger, A., Speakman, A., Fisher, M., Anderson, J., Collins, S., Hart, G., Sherr, L., Lampe, F. C., Johnson, M., McDonnell, J., Aderonke, A., Gilson, R., Edwards, S., Haddow, L., Gilson, S., Broussard, C., … Burman, B. (2014). Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: A cross-sectional comparison with the general population. The Lancet HIV, 1(1), e32–e40. https://doi.org/10.1016/S2352-3018(14)70018-9
   PubMed Web of Science ®Google Scholar
• Nduka, C., Sarki, A., Uthman, O., & Stranges, S. (2015). Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: A systematic review and meta-analysis. International Journal of Cardiology, 199, 307–318. https://doi.org/10.1016/j.ijcard.2015.07.052
   PubMed Web of Science ®Google Scholar
• Nduka, C., Stranges, S., Kimani, P. K., Sarki, A. M., & Uthman, O. A. (2017). Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes/Metabolism Research and Reviews, 33(6), https://doi.org/10.1002/DMRR.2902
   Google Scholar
• Nduka, C., Uthman, O., Kimani, P., & Stranges, S. (2016). Body fat changes in people living with HIV on antiretroviral therapy – PubMed. AIDS Review, 18(4), 198–211.
   PubMed Web of Science ®Google Scholar
• NIH. (2021). Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/what-start-initial-combination-regimens-antiretroviral-naive?view = full
   Google Scholar
• Obry-Roguet, V., Brégigeon, S., Cano, C. E., Lions, C., Zaegel-Faucher, O., Laroche, H., Galie, S., De Lamarlière, P. G., Orticoni, M., Soavi, M.-J., Saout, A., & Poizot-Martin, I. (2018). Risk factors associated with overweight and obesity in HIV-infected people aging, behavioral factors but not cART in a cross-sectional study. Medicine (Baltimore), 97(23), e10956. http://doi.org/10.1097/MD.0000000000010956.
   PubMed Web of Science ®Google Scholar
• O’Keefe, K. J., Scheer, S., Chen, M. J., Hughes, A. J., & Pipkin, S. (2013). People fifty years or older now account for the majority of AIDS cases in San Francisco, California, 2010. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 25(9), 1145–1148. https://doi.org/10.1080/09540121.2012.752565
   PubMed Web of Science ®Google Scholar
• Palella, F. J., Rayeed, N., Li, J., Ward, D., Fuhrer, J., Purinton, S., Tedaldi, E., Novak, R., & Buchacz, K. (2019). Weight gain among virally suppressed persons who switch to InSTI-based ART, The HIV Outpatient Study. Conference on Retroviruses and Opportunistic Infections.
   Google Scholar
• Pedersen, K. K., Eiersted, M. R., Gaardbo, J. C., Pedersen, M., Gerstoft, J., Troseid, M., & Nielsen, S. D. (2015). Lower self-reported quality of life in HIV-infected patients on cART and with low comorbidity compared with healthy controls. JAIDS Journal of Acquired Immune Deficiency Syndromes, 70(1), 16–22. https://doi.org/10.1097/QAI.0000000000000697
   PubMed Web of Science ®Google Scholar
• Pickard, A. S., Neary, M. P., & Cella, D. (2007). Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health and Quality of Life Outcomes, 5(1), 70. https://doi.org/10.1186/1477-7525-5-70
   PubMedGoogle Scholar
• Plankey, M., Bacchetti, P., Jin, C., Dass-Brailsford, P., Gustafson, D., Cohen, M. H., Karim, R., Yin, M., & Tien, P. C. (2013). The association of self-perception of body fat changes and quality of life in the Women’s Interagency HIV Study. AIDS Care, 25(12), 1544–1550. https://doi.org/10.1080/09540121.2013.793265
   PubMed Web of Science ®Google Scholar
• Sax, P. E., Erlandson, K. M., Lake, J. E., McComsey, G. A., Orkin, C., Esser, S., Brown, T. T., Rockstroh, J. K., Wei, X., Carter, C. C., Zhong, L., Brainard, D. M., Melbourne, K., Das, M., Stellbrink, H. J., Post, F. A., Waters, L., & Koethe, J. R. (2020). Weight gain following initiation of antiretroviral therapy: Risk factors in randomized comparative clinical trials. Clinical Infectious Diseases, 71(6), 1379–1389. https://doi.org/10.1093/cid/ciz999
   PubMed Web of Science ®Google Scholar
• Scévola, S., Tiraboschi, J. M., & Podzamczer, D. (2020). Nothing is perfect: The safety issues of integrase inhibitor regimens. Expert Opinion on Drug Safety, 19(6), 683–694. https://doi.org/10.1080/14740338.2020.1764531
   PubMed Web of Science ®Google Scholar
• Schackman, B. R., Fleishman, J. A., Su, A. E., Berkowitz, B. K., Moore, R. D., Walensky, R. P., Becker, J. E., Voss, C., Paltiel, A. D., Weinstein, M. C., Freedberg, K. A., Gebo, K. A., & Losina, E. (2015). The lifetime medical cost savings from preventing HIV in the United States. Medical Care, 53(4), 293. https://doi.org/10.1097/MLR.0000000000000308
   PubMed Web of Science ®Google Scholar
• Shah, K., Alio, A. P., Hall, W. J., & Luque, A. E. (2012). The physiological effects of obesity in HIV-infected patients. Journal of AIDS & Clinical Research, 03(4), 151. https://doi.org/10.4172/2155-6113.1000151.
   Google Scholar
• Shah, K., Hilton, T. N., Myers, L., Pinto, J. F., Luque, A. E., & Hall, W. J. (2012). A new frailty syndrome: Central obesity and frailty in older adults with the human immunodeficiency virus. Journal of the American Geriatrics Society, 60(3), 545–549. https://doi.org/10.1111/j.1532-5415.2011.03819.x
   PubMed Web of Science ®Google Scholar
• Shor-Posner, G., Campa, A., Zhang, G., Persaud, N., Miguez-Burbano, M.-J., Quesada, J., Fletcher, M. A., Page, J. B., & Baum, M. K. (2000). When obesity is desirable: A longitudinal study of the Miami HIV-1-infected drug abusers (MIDAS) cohort. JAIDS Journal of Acquired Immune Deficiency Syndromes (1999), 23(1), 81–88. https://doi.org/10.1097/00126334-200001010-00011
   PubMed Web of Science ®Google Scholar
• Shuter, J., Chang, C. J., & Klein, R. S. (2001). Prevalence and predictive value of overweight in an urban HIV care clinic. JAIDS Journal of Acquired Immune Deficiency Syndromes (1999), 26(3), 291–297. https://doi.org/10.1097/00126334-200103010-00013
   PubMed Web of Science ®Google Scholar
• Smit, C., Geskus, R., Walker, S., Sabin, C., Coutinho, R., Porter, K., & Prins, M. (2006). Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (London, England), 20(5), 741–749. https://doi.org/10.1097/01.AIDS.0000216375.99560.A2
   PubMed Web of Science ®Google Scholar
• Stellbrink, H., Arribas, J., Stephens, J., Albrecht, H., Sax, P., Maggiolo, F., Creticos, C., Martorell, C., Wei, X., Acosta, R., Collins, S., Brainard, D., & Martin, H. (2019). Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: Week 96 results from a randomised, double-blind, multicentre, phase 3, non-infer. The Lancet. HIV, 6(6), e364–e372. https://doi.org/10.1016/S2352-3018(19)30080-3
   PubMed Web of Science ®Google Scholar
• Strand, V., & Crawford, B. (2014). Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Review of Pharmacoeconomics & Outcomes Research, 5(3), 317–326. https://doi.org/10.1586/14737167.5.3.317
   Google Scholar
• Taramasso, L., Berruti, M., Briano, F., & Di Biagio, A. (2020). The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. Aids (London, England), 34(6), 877–881. https://doi.org/10.1097/QAD.0000000000002496
   PubMed Web of Science ®Google Scholar
• Tate, T., Willig, A. L., Willig, J. H., Raper, J. L., Moneyham, L., Kempf, M. C., Saag, M. S., & Mugavero, M. J. (2012). HIV infection and obesity: Where did all the wasting go? Antiviral Therapy, 17(7), 1281–1289. https://doi.org/10.3851/IMP2348
   PubMed Web of Science ®Google Scholar
• Tran, B. X., Ohinmaa, A., Nguyen, L. T., Nguyen, T. A., & Nguyen, T. H. (2011). Determinants of health-related quality of life in adults living with HIV in Vietnam. AIDS Care, 23(10), 1236–1245. https://doi.org/10.1080/09540121.2011.555749
   PubMed Web of Science ®Google Scholar
• UNAIDS. (2021). Global HIV & AIDS statistics – Fact sheet. https://www.unaids.org/en/resources/fact-sheet
   Google Scholar
• Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., Norris, S., Chersich, M., Clayden, P., Abrams, E., Arulappan, N., Vos, A., McCann, K., Simmons, B., & Hill, A. (2019). Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. New England Journal of Medicine, 381(9), 803–815. https://doi.org/10.1056/NEJMoa1902824
   PubMed Web of Science ®Google Scholar
• Ware, J., Kosinski, M., Bjorner, J., Turner-Bowker, D., Gandek, B., & Maruish, M. (2007). Determining important differences in scores. In User’s manual for the SF-36v2 health survey (2nd ed.). Quality Metric Inc. Lincoln.
   Google Scholar
• Ware, J. E., Kosinski, M., & Gandek, B. (2002). SF-36 Health Survey: Manual and Interpretation Guide.
   Google Scholar
• Warkentin, L. M., Majumdar, S. R., Johnson, J. A., Agborsangaya, C. B., Rueda-Clausen, C. F., Sharma, A. M., Klarenbach, S. W., Karmali, S., Birch, D. W., & Padwal, R. S. (2014). Weight loss required by the severely obese to achieve clinically important differences in health-related quality of life: Two-year prospective cohort study. BMC Medicine, 12, 175. https://doi.org/10.1186/S12916-014-0175-5.
   PubMed Web of Science ®Google Scholar
• Wing, E. J. (2017). The aging population with HIV infection. Transactions of the American Clinical and Climatological Association, 128(2), 131–144.
   Google Scholar
• Wohl, D. A., Yazdanpanah, Y., Baumgarten, A., Clarke, A., Thompson, M. A., Brinson, C., Hagins, D., Ramgopal, M. N., Antinori, A., Wei, X., Acosta, R., Collins, S. E., Brainard, D., & Martin, H. (2019). Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: Week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet HIV, 6(6), e355–e363. https://doi.org/10.1016/S2352-3018(19)30077-3
   PubMed Web of Science ®Google Scholar
• Womack, J., Tien, P. C., Feldman, J., Shin, J. H., Fennie, K., Anastos, K., Cohen, M. H., Bacon, M. C., & Minkoff, H. (2007). Obesity and immune cell counts in women. Metabolism, 56(7), 998–1004. https://doi.org/10.1016/j.metabol.2007.03.008
   PubMed Web of Science ®Google Scholar
• Zanini, A., Aiello, M., Adamo, D., Casale, S., Cherubino, F., Patrona, S. D., Raimondi, E., Zampogna, E., Chetta, A., & Spanevello, A. (2015). Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD. Respiratory Care, 60(1), 88–95. https://doi.org/10.4187/respcare.03272
   PubMed Web of Science ®Google Scholar